# Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

> **NCT00175643** · PHASE3 · COMPLETED · sponsor: **University of British Columbia** · enrollment: 20 (—)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** imiquimod

## Key facts

- **NCT ID:** NCT00175643
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 20 (—)
- **Last updated:** 2006-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175643, "Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00175643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*